Skip to main
PMN
PMN logo

PMN Stock Forecast & Price Target

PMN Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ProMIS Neurosciences Inc demonstrates a promising outlook as favorable biomarker and safety data related to its lead candidate, PMN310, indicate a mechanistic advantage that bolsters rationale for continued investment ahead of forthcoming 12-month results. Additionally, the strong selectivity profile of PMN267, which is advancing toward clinical development, suggests potential for effective disease-modifying activity and an enhanced safety margin across various neurodegenerative diseases, including ALS and frontotemporal dementia. Collectively, these factors highlight the company's strategic positioning within the biotechnology sector, underpinned by its innovative methodologies for targeting toxic misfolded proteins.

Bears say

ProMIS Neurosciences faces a negative outlook due to several fundamental issues highlighted in the recent financial excerpts. There is a concern regarding the effectiveness of its lead treatment, PMN310, despite showing some promise in restoring learning and spatial memory in animal models, as the overall success of therapies targeting neurodegenerative diseases has been historically limited by complex mechanistic understandings and poor correlation with clinical outcomes. Additionally, the potential for partnership risks, slower-than-anticipated market uptake due to competition, and the looming threat of dilution further complicate the company's financial stability and growth prospects.

PMN has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ProMIS Neurosciences Inc (PMN) Forecast

Analysts have given PMN a Strong Buy based on their latest research and market trends.

According to 3 analysts, PMN has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ProMIS Neurosciences Inc (PMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.